Dexmethylphenidate

Focalin and Focalin XR are U.S. prescription ADHD products containing a Schedule II controlled stimulant. The IR label establishes pediatric efficacy at age 6–17; its dose instructions specify pediatric patients. XR provides adult and pediatric regimens and established pediatric efficacy from age 6. Neither selected label indicates narcolepsy.

XR is not recommended below age 6 because younger children had higher exposure and more adverse reactions, including weight loss, with extended-release methylphenidate products. IR safety/effectiveness below age 6 is unestablished. An adult XR regimen should not be presented as the pediatric IR label regimen.

For pediatric patients new to methylphenidate or taking a different stimulant, start 2.5 mg twice daily, at least 4 hours apart, with or without food. Increase weekly by 2.5–5 mg/day according to response; maximum 20 mg/day (10 mg twice daily). For a switch from racemic methylphenidate, the starting daily dose is half its total daily milligram dose.

Take XR once each morning with or without food. These are label starting regimens, not automatic dose substitutions for unrelated stimulant products.

Swallow XR whole, or open it and sprinkle the entire contents on applesauce; swallow immediately without chewing and do not store the mixture. Do not divide capsule contents. Reduce the dose or stop for paradoxical worsening or adverse effects. Both labels recommend discontinuation if appropriate adjustment produces no improvement after a month.

Do not use after hypersensitivity to methylphenidate or formulation ingredients, or with an MAOI or within 14 days after its discontinuation because of hypertensive-crisis risk. Serious cardiac disease and glaucoma precautions should retain their actual warning classification.

The boxed warning describes high potential for abuse and misuse, substance use disorder including addiction, and overdose or death; risk rises with high doses or unapproved routes. Assess risk before prescribing, educate patients and families, and reassess frequently. Store securely, preferably locked, never share, and dispose of unused medication appropriately.

Reported effects include decreased appetite, abdominal pain, nausea, headache, insomnia, and anxiety; the trial patterns differ by age and formulation. Withdrawal after prolonged use may produce depression, fatigue, sleep disturbance, and increased appetite. Overdose can cause arrhythmias, severe blood-pressure changes, agitation, seizures, serotonin syndrome, hyperthermia, and rhabdomyolysis. Obtain emergency toxicology care; U.S. Poison Help is 1-800-222-1222. XR release must be considered when assessing toxicity.

MAOIs are contraindicated concurrently and for 14 days after stopping them. Antihypertensive efficacy can fall; monitor and adjust the antihypertensive as needed. Avoid stimulant dosing on the day of surgery when halogenated anesthetics are used. With risperidone, changes in either drug’s dose may increase extrapyramidal symptoms; monitor for abnormal movements.

Metabolism is primarily de-esterification rather than a clinically important CYP pathway; routine CYP inhibitor dose rules should not be imported from amphetamine products. Postmarketing methylphenidate reports include serotonin syndrome with serotonergic medicines; assess symptoms and the whole medication list rather than assigning an unsupported numerical interaction dose.

The labels summarize published methylphenidate pregnancy studies without an identified major-outcome signal but retain potential fetal concerns from CNS stimulant vasoconstriction and animal findings. This is not proof of dexmethylphenidate safety. Limited milk data also concern methylphenidate; long-term infant neurodevelopment is unknown. Weigh maternal need and breastfeeding benefits, and monitor the infant for agitation, insomnia, reduced appetite, and poor weight gain. A pregnancy exposure registry is described in the labels.

Pediatric safety/effectiveness is established at age 6–17. XR is specifically not recommended under age 6; IR is unestablished there. Monitor height and weight throughout therapy. Both selected formulations lack geriatric studies; do not extrapolate trial reassurance to older adults.

Neither label reports experience in renal or hepatic impairment. Renal dysfunction is expected to have little pharmacokinetic effect because parent-drug renal clearance is minor; that expectation is not a validated organ-specific dosing algorithm. No numerical hepatic adjustment is supplied.

Methylphenidate inhibits dopamine and norepinephrine reuptake and increases extracellular monoamines; the precise therapeutic mode of action in ADHD is unknown. Dexmethylphenidate is the more active d-enantiomer, explaining why racemic methylphenidate milligram doses are not simply copied.

IR reaches peak concentrations at approximately 1–1.5 hours fasting, with a mean terminal half-life about 2.2 hours. XR produces two peaks through immediate and delayed bead release. Dexmethylphenidate is converted mainly to minimally active d-ritalinic acid; metabolites are predominantly recovered in urine. Food can alter peak timing, while labeled administration permits use with or without food.

Before starting, obtain cardiac and family sudden-death/arrhythmia history and examination, tic/Tourette history, and psychiatric risk assessment. During titration and continuing care, follow response, BP/pulse, appetite, sleep, height/weight, mood or psychotic symptoms, digital circulation, tics, and misuse/diversion. Reassess medication interactions and glaucoma risk.

Take only as prescribed and never share or change the route. Keep medicine locked and arrange proper disposal. Report chest pain, fainting, new hallucinations or mania, painful erections, finger/toe color changes or sores, and acute eye symptoms promptly. Follow XR applesauce instructions exactly. Discuss pregnancy, breastfeeding, anesthesia, or prolonged discontinuation with the prescriber.

Sandoz Focalin 5-mg IR tablets are yellow, D-shaped, marked D and 5; the 100-tablet bottle is NDC 66758-251-01. Novartis Focalin XR 10-mg capsules are light caramel, marked NVR D10; the 100-capsule bottle is NDC 0078-0431-05. These reference identities do not guarantee current stock availability.

Focalin IR tablets: 2.5, 5, and 10 mg. Selected Focalin XR capsules: 5, 10, 15, 20, 25, 30, 35, and 40 mg. Strengths denote dexmethylphenidate hydrochloride. A marketed strength is not a pediatric permission to exceed the 30-mg/day XR recommendation.

Store both at 20–25°C, with excursions to 15–30°C, in tight containers. IR additionally requires protection from light and moisture and a light-resistant container. Secure against theft or accidental use; discard unused medication according to the label’s safe-disposal instructions.